18.11.2010 • NewsSTEP Awardbiopharmaceuticals

STEP Award: Glycotope Wins in 2010

Glycotope, a leading glycobiology company, was awarded with the 2010 STEP-Award for financing on Wednesday.

Glycotope was selected for its strategically aligned and long-term funding concept.

CFO Dr. Franzpeter Bracht stated, "In addition to our outstanding technology, from the beginning we have put great emphasis on a balanced mix of revenues and investments."

"The extraordinary financial commitment by Drs. Thomas and Andreas Strüngmann has been of tremendous help though and secured the long term growth of our company, based on our outstanding technology the basis for our largely improved biopharmaceuticals developed by our CEO, CSO and founder Dr. Steffen Goletz" said Dr. Hans Baumeister, COO.

Even ahead of entering pipeline- and technology-related licensing agreements, Glycotope has thus been able to cover a large proportion of its expenditures via its contract research, manufacturing and diagnostics business.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.